Table 5.

Incidence of malignancies in the RA DMARD cohorts*

	BC	NDB	GPRD	NOAR	Sweden ERA
Total malignancies (excluding NMSC)	1274	NA†	472	30	148
	1.77 (1.51 to 2.08)		0.67 (0.51 to 0.87)	0.73 (0.56 to 0.93)	0.71 (0.55 to 0.92)
Breast cancer	205	156	94	4	13
	0.34 (0.24 to 0.49)	0.28 (0.19 to 0.42)	0.16 (0.09 to 0.28)	0.14 (0.08 to 0.25)	0.11 (0.06 to 0.21)
Colorectal cancer	139	52	40	2	20
	0.14 (0.08 to 0.24)	0.06 (0.03 to 0.15)	0.05 (0.02 to 0.13)	0.05 (0.02 to 0.13)	0.06 (0.02 to 0.14)‡
Lung cancer	218	116	109	4	23
	0.26 (0.17 to 0.39)	0.12 (0.07 to 0.22)	0.14 (0.08 to 0.25)	0.09 (0.04 to 0.18)	0.13 (0.07 to 0.23)
Lymphoma	94	35	41	3	11
	0.11 (0.06 to 0.21)	0.08 (0.04 to 0.17)	0.06 (0.02 to 0.14)	0.07 (0.03 to 0.16)	0.06 (0.02 to 0.14)

Values represent numbers of incident cancer cases and incidence rates (IR) per 100 person-years (95% CI). *Rates adjusted to the age and sex distribution of the abatacept clinical trial patients. ^†This outcome was not available for the NDB. ^‡The Sweden ERA cohort for the colorectal cancer analysis consists of 4295 patients rather than the 3703 used for the other malignancies.

BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB, National Data Bank for Rheumatic Diseases; NMSC, non-melanoma skin cancer; NOAR, Norfolk Arthritis Register; RA, rheumatoid arthritis; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.